1 day ago
Summit Therapeutics (SMMT) Stock Hits 52-Week Low After FDA Rejects Lung Cancer Drug
TLDR SMMT traded near $11.70 premarket Monday, down about 17% to a new 52-week low. The FDA issued a Complete Response Letter for ivonescimab in EGFR-mutated lung cancer. The agency wants proof of an overall survival benefit that clears the statistical bar. Jefferies sees limited downside, and Barclays cut its target to $18 from $20. [...]
The post Summit Therapeutics (SMMT) Stock Hits 52-Week Low After FDA Rejects Lung Cancer Drug appeared first on Blockonomi.
Source: Blockonomi →Related News
- 1 hour ago
Vertiv Holdings (VRT) Stock: Expands 800 VDC Power Systems for AI Data Centers
- 1 hour ago
Coinbase CEO says AI agents will account for '99.9%' of transactions within a de...
- 1 hour ago
Penguin Solutions, Inc. (PENG) Stock: Unveils ClusterWareAI 13.3 for NVIDIA Vera...
- 2 hours ago
Ciena Corporation (CIEN) Stock: Hits New 800G Network Record With Internet2
- 2 hours ago
Predictions platform Kalshi complies with order to halt Trump mention contracts
